Integrum provides an update on the clinical development programs of e-OPRA[TM] Implant System and Neuromotus[TM]
Mölndal, Sweden, November 30[th], 2022 – Integrum (publ) (Nasdaq First North Growth Market: INTEG B) today provides an update on the clinical development of its mobility-transforming implant solution e-OPRA[TM] Implant System, and Neuromotus[TM] – a cutting-edge technology developed to prevent severe pain in limb loss patients.e-OPRA[TM] Implant System The clinical development of e-OPRA™ Implant System focuses not only on providing prosthesis users with the benefits of a bone-anchored implant solution but also on the possibilities of mind-controlled artificial limb movement, as well as